CG
FATE icon

Cutler Group’s Fate Therapeutics FATE Stock Holding History

Cutler Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-209
Closed -$12K – 5528
2021
Q4 		$12K Sell
209
-2,000
-91% -$113K ﹤0.01% 3533
2021
Q3 		$130K Buy
2,209
+2,059
+1,373% +$162K 0.01% 1704
2021
Q2 		$13K Hold
150
– – ﹤0.01% 3671
2021
Q1 		$12K Sell
150
-1,230
-89% -$118K ﹤0.01% 3640
2020
Q4 		$125K Buy
+1,380
New +$85.7K 0.01% 1388
2020
Q3 		– Sell
-1,300
Closed -$45.4K – 4833
2020
Q2 		$44K Buy
+1,300
New +$38.7K ﹤0.01% 1833
2020
Q1 		– Sell
-700
Closed -$17.7K – 4185
2019
Q4 		$13K Buy
+700
New +$11.1K ﹤0.01% 2482
2018
Q3 		– Sell
-1,000
Closed -$11.8K – 4274
2018
Q2 		$11K Buy
+1,000
New +$11K ﹤0.01% 2596

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Cutler Group's FATE Position: Q1 2022 in Review

Cutler Group sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 209 shares — an estimated $12K sold.

Cutler Group first reported a position in FATE in Q2 2018 and held it in 8 quarters. The position peaked at $130K in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Cutler Group reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 209 Fate Therapeutics shares in Q1 2022, an estimated $12K.
  • Cutler Group first reported a position in Fate Therapeutics in Q2 2018 and held it in 8 quarters.
  • Cutler Group's Fate Therapeutics position peaked at $130K in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.